This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Robert Bear, MD, FRCP

Arch Intern Med. 1988;148(11):2343-2344.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The angiotensin-converting enzyme inhibitor (ACEI), enalapril maleate, is a nonsulfydryl group—containing compound. Accordingly, it is said to be less associated with side effects such as taste disturbance, rashes, proteinuria, and interstitial nephritis; these side effects having been observed with captopril, and attributed to its sulfydryl group. Enalapril is a pro-drug. Because the active compound, enalaprilic acid, is poorly absorbed, the drug is given as an absorbable ester, which is then hydrolyzed to the active compound. This results in a more gradual onset of antihypertensive effect than may be seen with captopril. However, enalapril is a more potent ACEI than captopril, and its pharmacologic half-life is prolonged, permitting once daily dosage.

See also p 2358.

The consequences of ACEI therapy are complex, multidimensional, and imperfectly understood.¹ The inhibition of the enzyme that converts the inactive decapeptide angiotensin-I into the potent pressor agent angiotensin-II has systemic and intrarenal consequences. Systemically, decreased . . . [Full Text PDF of this Article]

Author Affiliations
St Michael's Hospital Annex 38 Shuter St Toronto, Ontario, Canada M5B 1A6

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?